These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9727728)

  • 41. Pindolol augmentation enhances response outcomes in first depressive episodes.
    Portella MJ; de Diego-Adeliño J; Puigdemont D; Pérez-Egea R; Alvarez E; Artigas F; Pérez V
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):516-9. PubMed ID: 19419845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
    Crown WH; Treglia M; Meneades L; White A
    Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effective treatment of depression with selective serotonin reuptake inhibitors.
    Panzarino PJ; Nash DB
    Am J Manag Care; 2001 Feb; 7(2):173-84. PubMed ID: 11216334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI.
    Ahrold TK; Meston CM
    J Sex Marital Ther; 2009; 35(4):311-9. PubMed ID: 19466669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
    JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials.
    Ballesteros J; Callado LF
    J Affect Disord; 2004 Apr; 79(1-3):137-47. PubMed ID: 15023488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
    Polsky D; Onesirosan P; Bauer MS; Glick HA
    J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression.
    Segrave R; Nathan PJ
    Hum Psychopharmacol; 2005 Apr; 20(3):163-74. PubMed ID: 15648095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency?
    Kinney GG; Taber MT; Gribkoff VK
    Mol Neurobiol; 2000 Jun; 21(3):137-52. PubMed ID: 11379796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute tryptophan depletion in depressed patients treated with a selective serotonin-noradrenalin reuptake inhibitor: augmentation of antidepressant response?
    Booij L; Van der Does AJ; Haffmans PM; Riedel WJ
    J Affect Disord; 2005 Jun; 86(2-3):305-11. PubMed ID: 15935252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man.
    Schmitt JA; Ramaekers JG; Kruizinga MJ; van Boxtel MP; Vuurman EF; Riedel WJ
    J Psychopharmacol; 2002 Sep; 16(3):207-14. PubMed ID: 12236626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
    Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN
    Value Health; 2000; 3(3):208-21. PubMed ID: 16464185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
    Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
    Blier P; Bergeron R; de Montigny C
    Neuropsychopharmacology; 1997 May; 16(5):333-8. PubMed ID: 9109104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Penetrating the blind in a study of an SSRI.
    Piasecki MP; Antonuccio DO; Steinagel GM; Kohlenberg BS; Kapadar K
    J Behav Ther Exp Psychiatry; 2002 Jun; 33(2):67-71. PubMed ID: 12472171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.
    Pérez V; Gilaberte I; Faries D; Alvarez E; Artigas F
    Lancet; 1997 May; 349(9065):1594-7. PubMed ID: 9174562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.